SPONSOR
The First Affiliated Hospital of Zhengzhou University
Total Trials
8
Recruiting
8
Phases
Phase 2, Phase 4
Conditions studied: Brain GliomaEsophageal CancerChronic Total Occlusions of Coronary ArteriesChronic Total Occlusion (CTO)Coronary Artery Disease (CAD)Female, Age ≥ 18 Years OldNo Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/ImmunotherapyECOG Score of 0-1Histologically Confirmed Cervical Cancer, FIGO Stage IB3, IIA2, IIB, IIIC, and Assessed by the Researcher as Resectable LesionSufficient Organ Function
The First Affiliated Hospital of Zhengzhou University is a clinical research sponsor with 8 registered studies on ClinicalTrials.gov, of which 8 are actively recruiting participants. Research covers conditions including Brain Glioma, Esophageal Cancer, Chronic Total Occlusions of Coronary Arteries, Chronic Total Occlusion (CTO).
The trial portfolio spans Phase 2, Phase 4 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — The First Affiliated Hospital of Zhengzhou University
How many clinical trials has The First Affiliated Hospital of Zhengzhou University sponsored?
ClinicalMetric currently tracks 8 clinical trials sponsored by The First Affiliated Hospital of Zhengzhou University, of which 8 are actively recruiting participants. These trials cover conditions including Brain Glioma, Esophageal Cancer, Chronic Total Occlusions of Coronary Arteries. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does The First Affiliated Hospital of Zhengzhou University research focus on?
The First Affiliated Hospital of Zhengzhou University clinical trials span Brain Glioma, Esophageal Cancer, Chronic Total Occlusions of Coronary Arteries, Chronic Total Occlusion (CTO), Coronary Artery Disease (CAD), and additional conditions. The research pipeline includes Phase 2, Phase 4 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a The First Affiliated Hospital of Zhengzhou University clinical trial?
To participate in a The First Affiliated Hospital of Zhengzhou University trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all The First Affiliated Hospital of Zhengzhou University trials with current recruitment status updated daily.
Clinical Trials by The First Affiliated Hospital of Zhengzhou University
NCT06747728
Recruiting
Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain
Brain Glioma
NCT06718205 Phase 2
Recruiting
Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
Esophageal Cancer
NCT07463664
Recruiting
Clinical Outcomes of Drug-Coated Balloons in the Treatment of Patients With Coronary De Novo Chronic Total Occlusion Lesions
Chronic Total Occlusions of Coronary Arteries
NCT07104149 Phase 2
Recruiting
Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer
Female, Age ≥ 18 Years Old
NCT06564545 Phase 2
Recruiting
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL
Acute Lymphoblastic Leukemia, Adult
NCT04217044
Recruiting
Histopathology Images Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence
Glioma
NCT06930573 Phase 4
Recruiting
A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
HCC
NCT05738434 Phase 2
Recruiting
Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC
Esophageal Cancer by AJCC V8 Stage
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology